1. A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients
- Author
-
Davide Sangalli, Chiara Scaccabarozzi, Vittorio Mantero, Daniele Colombo, Marco Filizzolo, Valeria Polonia, and Andrea Salmaggi
- Subjects
Male ,medicine.medical_specialty ,Neurology ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Pneumonia, Viral ,Clinical Neurology ,Dermatology ,Tissue plasminogen activator ,Intravenous thrombolysis ,Brain Ischemia ,Brain ischemia ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,rt-PA ,Thrombolytic Therapy ,030212 general & internal medicine ,Pandemics ,Stroke ,Aged ,Neuroradiology ,SARS-CoV-2 ,business.industry ,COVID-19 ,General Medicine ,Thrombolysis ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Psychiatry and Mental health ,Tissue Plasminogen Activator ,Emergency medicine ,Administration, Intravenous ,Female ,Neurology (clinical) ,Neurosurgery ,Coronavirus Infections ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The sudden worldwide outbreak of Coronavirus Disease 2019 (COVID-19) has certainly provided new challenges in the management of acute ischaemic stroke, and the risk-benefit ratio of intravenous thrombolysis in COVID-19 positive patients is not well known. We describe four COVID-19 patients treated with intravenous thrombolysis for acute ischaemic stroke. Although rt-PA administration is the main therapeutic strategy, our patients experienced unpredictable complications and showed atypical features: the overall mortality was very high. In conclusion, in this article, we provide information about these cases and discuss the possible explanation behind this trend.
- Published
- 2020
- Full Text
- View/download PDF